DiaSorin SpA (0GZX)
London Exchange · UK · prices in EUR · close of 20 Oct 2026
Key indicators
| Last close | EUR 78.76 |
|---|---|
| 52-week range | 50.19 – 80.00 |
| Return, 1 month / 3 months | +1.3% / +17.1% |
| Return, 1 year / 3 years | +5.8% / −2.3% |
| Trend | Uptrend |
| RSI (14) | 58 |
| Volatility (1 year) | 39.6% |
| Worst drawdown (1 year) | -29.3% |
| Average daily value traded | 0.73M EUR |
| Dividend yield | 1.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
DiaSorin is an Italian company that develops and makes diagnostic tests and laboratory instruments. Its immunodiagnostics and molecular testing products help clinical laboratories, hospitals and blood banks detect and monitor disease. The company also supplies the reagents and automated systems that laboratories use to run these tests. DiaSorin is based in Saluggia, in northern Italy, and serves healthcare customers in many countries.
The shares are listed on the London Exchange in UK under the code 0GZX, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
DiaSorin SpA (0GZX) trades on the London Exchange in UK. It last closed at EUR 78.76 on 20 October 2026.
Its price-based Market X-Ray is 63 out of 100 (a fair price profile), ranking 1,065 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 5.8% and over the last three months it rose 17.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 84 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 13.6% | ||
| From 52-week high | -0.6% | ||
| Momentum | 75 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 17.1% | ||
| 6-month return | 28.9% | ||
| 12-month return, skipping the last month | 4.4% | ||
| Stability (higher is calmer) | 45 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 39.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.3% | ||
| Liquidity | 49 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.73M EUR | ||
| Zero-volume days | 5.0% | ||
| Income | 48 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.7% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.9% |
|---|---|
| 1 month | +1.3% |
| 3 months | +17.1% |
| 6 months | +28.9% |
| 1 year | +5.8% |
| 3 years | −2.3% |
| 5 years | −55.8% |
Signals
| 50-day / 200-day average | 75.98 / 69.34 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.83 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 May 2026 | EUR 1.3000 |
| 19 May 2025 | EUR 1.2000 |
| 20 May 2024 | EUR 1.1500 |
| 22 May 2023 | EUR 1.1000 |
| 23 May 2022 | EUR 1.0500 |
| 24 May 2021 | EUR 1.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.